Developing Therapeutics For Ischemic Disease




MIFCOR is a platform company that is building on the body's natural defense mechanisms to develop therapies that reduce tissue damage associated with heart attacks, acute kidney injury, and other indications.


Reducing tissue death following traumatic injury to vital organs can drastically improve the quality of life, yet no effective therapies currently exist in the market.

Clinical Candidates


MIFCOR's patented compounds induce pro-survival mechanisms in cells undergoing ischemia. Therapeutic candidates include the protein MIF-2 and  small molecule MIF20, which have a known a mechanism of action and proven in vivo efficacy.  


MIF-2 and MIF20 have the potential to extend the lives of 30 million Americans each and every year.